Duchenne Muscular Dystrophy (DMD) impacts millions globally, necessitating a robust market for effective treatments. The present DMD treatment landscape is characterized by the focus on symptom management and supportive care. However, recent advances in gene therapy and medications are creating the way for potential curative solutions. Research ar